BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28881547)

  • 21. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand.
    Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Deebukkham P; Kulkarni AS; Pavelyev A
    PLoS One; 2021; 16(2):e0245894. PubMed ID: 33571186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies.
    Canfell K; Shi JF; Lew JB; Walker R; Zhao FH; Simonella L; Chen JF; Legood R; Smith MA; Nickson C; Qiao YL
    Vaccine; 2011 Mar; 29(13):2487-94. PubMed ID: 21211586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Economic evaluation of fifteen cervical cancer screening strategies in rural China].
    Wang YY; Wang ZJ; Zhang Y; Gao XH; Yang CX; Zhao FH; Qiao YL; Ma L; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2019 Dec; 54(12):840-847. PubMed ID: 31874474
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
    Jit M; Brisson M; Laprise JF; Choi YH
    BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
    Obradovic M; Mrhar A; Kos M
    Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.
    Zhang Q; Liu YJ; Hu SY; Zhao FH
    BMC Cancer; 2016 Nov; 16(1):848. PubMed ID: 27814703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
    Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach.
    Vanni T; Luz PM; Foss A; Mesa-Frias M; Legood R
    Vaccine; 2012 Jul; 30(32):4866-71. PubMed ID: 22652405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
    BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women.
    Ma X; Harripersaud K; Smith K; Fairley CK; Zou H; Zou Z; Wang Y; Zhuang G; Zhang L
    Hum Vaccin Immunother; 2021 Apr; 17(4):1073-1082. PubMed ID: 33269990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
    Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.